Fulgent Genetics (FLGT) Stock Analysis & AI Equity Report

Medical - Diagnostics & Research USD Explore free reports

Fulgent Genetics (FLGT) overview

Fulgent Genetics (FLGT) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 323m and operating profit of USD -91.1m; the year-end share price was 26.27 USD and market capitalisation was USD 816m. Fulgent Genetics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Fulgent Genetics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 1,112mFY 2025
Share price26.27 USDFY 2025 year end
RevenueUSD 323mFY 2025
Operating profitUSD -91.1mFY 2025
Net earningsUSD -60.5mFY 2025
Market capitalisationUSD 816mFY 2025 year end

About Fulgent Genetics

Fulgent Genetics provides laboratory testing and therapeutic development services. Its laboratory business offers anatomic pathology, genetic and precision diagnostic testing, including oncology, rare disease, hereditary cancer and reproductive health services. It also serves pharmaceutical and biotechnology companies with testing, licensing and sponsored programs, and offers consumers testing through a telemedicine platform. Its therapeutic business develops cancer drug candidates using nanoencapsulation technology.

Generate the Fulgent Genetics report

Fulgent Genetics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Fulgent Genetics and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Fulgent Genetics

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.